While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, ...

Novo filed its lawsuit in the summer, accusing Lilly of a "nationwide pattern of deceptive advertising" for its obesity ...

At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy ...

First teased earlier this year, the phase 3 CLARITY-Gastric01 study included previously treated patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or ...

UK biotech sector has shrugged off a difficult economic environment with a 44% increase in venture capital investment in the ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

Covering the Congress onsite at Messe Berlin, pharmaphorum interviewed experts in their field and reported from the broad oncological programme of presentations itself. Key areas ...

In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy epilepsy drug developer Actio Biosciences in a deal that includes an upfront payment of $820 million. Privately-held Actio is ...